The Process Is the Product. Change It and You Have Made Something Else.
Regulatory strategy for BLA-path proteins and antibodies — where comparability is a strategy, not a formality, and every process change is a scientific argument.
You Cannot Fully Characterize a Biologic. You Can Only Control How It Is Made.
A small molecule can be defined by its structure — prove the structure, and identity follows. A monoclonal antibody cannot. It is a population of related molecules with glycosylation profiles, charge variants, and aggregates that emerge from living cells reacting to bioreactor conditions. Analytics have improved enormously, but the fundamental asymmetry holds: the process defines the product in ways the analytics only partly see.
Everything distinctive about biologics regulation follows from that. Comparability exercises when you change anything. Potency assays that measure biological activity rather than purity. Immunogenicity risk that no structural assay predicts reliably. And a control strategy where the cell line, the media, and the bioreactor parameters are as much a part of the file as the specifications.
Cells respond to their environment. That is why they make your drug — and why they can change it.
Every Process Change Puts Two Things on the Scales.
ICH Q5E comparability is the discipline that decides whether a change costs a memo or a clinical study. It is not a test — it is a weighted argument.
The Process Move
Every one of these has triggered a comparability exercise in a real program.
- Site transfer — the same equipment in a different building is still a change
- Scale-up: 2,000 L to 15,000 L alters shear, oxygen transfer, and glycosylation
- Cell line or master cell bank changes — the highest-stakes version
- Raw material or media supplier substitutions
- Purification resin or filter changes affecting impurity clearance
The Evidence
The tiered argument — and you only climb the tiers if the lower one leaves doubt.
- Analytical: extended characterization, side by side, pre- and post-change
- Functional: potency and binding — biological activity, not just purity
- Nonclinical / PK: when analytics leave a residual question
- Clinical: the expensive tier — where a badly planned change lands
The fulcrum is your analytical package. Strong characterization lets a change be argued on the bench; weak characterization pushes the same change into the clinic. That is why we invest in analytics before the first change request — it is the cheapest insurance in biologics development.
A biological assay with real variability, on the critical path, forever.
Potency and Immunogenicity Are Where Biologics Programs Actually Bleed.
A potency assay has to reflect the mechanism of action, which means it is usually cell-based, which means it is variable, slow, and on the critical path for every lot release for the life of the product. Programs that treat potency as an analytical afterthought discover it during BLA review, when the assay’s variability is suddenly the reason your specification cannot be justified.
Immunogenicity is the other one. Anti-drug antibodies can neutralize efficacy or cause reactions, and no structural characterization predicts them reliably — so the answer is a tiered bioanalytical strategy planned from first-in-human, not assembled for the filing. We build the potency and immunogenicity strategies early, because both are cheap in Phase 1 and brutal in Module 3.
What a Biologics Program Plans Around.
Three realities that shape every decision from cell line to launch.
Comparability: the framework that decides whether your process change costs a memo or a clinical study.
Your product’s origin story. Characterize it once, properly — every batch for thirty years traces back to it.
A biological assay on the critical path for every lot, forever. Design it like the product depends on it.
Six Failure Modes We Are Brought In to Prevent.
Biologics punish decisions made years before anyone realizes they were decisions.
Scale-up without a comparability plan
Commercial material that is not the clinical material, discovered when the glycan profile shifts and there is no bridging strategy.
Potency assay left too late
A cell-based assay with variability that cannot support a specification, on the critical path, in review.
Cell bank under-characterized
A master cell bank documented for a research project rather than a thirty-year commercial product.
Immunogenicity strategy assembled at BLA
No tiered bioanalytical plan from Phase 1, and a reviewer asking questions the sample archive cannot answer.
Raw materials with no control
Media components and single-use plastics changing upstream, with extractables nobody assessed.
CDMO owns the knowledge
A contract manufacturer holding the process understanding your file depends on, and a tech transfer you cannot execute.
Biologics Leadership That Has Defended the Process.
Our biologics leads have run comparability exercises, built potency strategies, and carried BLAs through review and inspection.
“In biologics, your analytical package is not documentation — it is leverage. It decides whether your next process change is an argument or a clinical trial.”
The discipline we bring to antibodies, recombinant proteins, and complex biologics.
Developing a Biologic? Build the Analytics Before You Need the Argument.
Bring senior biologics leadership in before the first process change — comparability is won with characterization you already have.
Senior-led. Embedded in your team. No junior hand-offs.